Looks like the FDA sprung for an open bar at their holiday party because we got another FDA approval.

Let’s catch you up on the approval of Rhopressa at the end of 2017.

What is Rhopressa?
A once daily eye drop to lower IOP for patients with open angle glaucoma or ocular hypertension.

How does it work?

The main buzz word you will hear is that it’s a ROCK inhibitor.
Rock Inhibitors increase outflow through the trabecular meshwork by inhibiting Rho Kinase (ROCK). Rhopressa is also presumed to work via two other mechanisms:
— It reduces fluid production in the eye by inhibiting the norepinephrine transporter (NET Inhibitor).
— It lowers episcleral venous pressure.

What are the side effects?
The biggest one was conjunctival hyperemia reported in 53% of patients. Others were corneal verticillata (aka vortex keratopathy), instillation site pain, and conjunctival hemorrhage.

Tell me about the clinical trials.
There were three trials (123) with over 1800 participants. The studies compared Rhopressa to Timolol. All the studies showed up to 5 mmHg reductions in IOP with Rhopressa.

Interestingly, for patients with IOP at 25 mmHg or higher, Timolol had a better IOP reduction than Rhopressa. This has lead many doctors to ask if Rhopressa is better suited for patients with lower baseline IOP.

When can I prescribe it?
Likely by the second quarter of 2018 but you’ll start seeing reps for this soon.
(full prescribing info here)

Get in Touch


Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts